An orally active SYK inhibitor, fostamatinib, has already received FDA approval as a treatment for immune thrombocytopenia and continues to be investigated as an experimental therapy for hematological malignancies (NCT00446095). This evidence concerns the gene SYK and autoimmune thrombocytopenic purpura.